- Tags: retina
Research
Could DR screenings benefit CVD detection?
Study explores potential of unexpected early advantages for patients with type 2 diabetes mellitus during routine eye exams.
Research
Clinicians are under-utilizing this AI-based DR screening system
EyeArt system demonstrates high diagnostic accuracy in detecting DR, though obstacles remain for real-world implementation.
Research
Study links DME to systemic microvascular complications in diabetes
Analysis highlights the interconnected relationship between DR, neuropathy, and nephropathy in T2DM.
Pipeline
SeaBeLife and Unither to formulate and develop retinal degenerative disorder formulation
Collaboration focuses on accelerating development of SBL03, formulated for topical delivery to target retinal cell necrosis in GA and dry AMD
Pipeline
Ocular Therapeutix plans for NDA submission of AXPAXLI for wet AMD
Company expects to submit package in Q1 2026, following the anticipated release of positive 1-year data from the phase 3 SOL-1 trial.
Research
Lifestyle behaviors play major role in preventing genetic risk for advanced AMD
Study assesses if lifestyle behaviors can offset the risk of AMD progression in those with high genetic susceptibility.
Pipeline
FDA clears Zhongmou Therapeutics' IND for RP optogenetic gene therapy
Clearance of ZM-02 marks the first optogenetic gene therapy originating from China to receive U.S. IND authorization.
Pipeline
Belite Bio reports phase 3 topline data on oral tinlarebant for Stargardt disease
DRAGON study is evaluating the once-daily tablet for reducing lesion growth among adolescent patients over a 24-month period.
Products
Evoq launches FDA-registered dark adaptation testing device for IRDs
The Twilight is a wearable and smartphone-based diagnostic tool for at-home, remote monitoring of retinal health and early retinal disease detection.
Research
Analysis: Global DR cases on the rise, sparking urgent need for intervention
Study highlights concerning global, regional, and national trends in DR-related blindness.
Products
FDA approves new EYLEA HD indication, expanded dosing intervals
Intravitreally-administered 2 mg aflibercept therapeutic is now cleared for macular edema following retinal vein occlusion.
Research
DR risk may significantly increase with low hemoglobin levels
New research found low levels independently increased the risk among diabetic patients—with a strong association for proliferative DR.
Pipeline
Coave Therapeutics debuts lead SCS gene therapy for retinal vascular diseases
In-office, suprachoroidal delivery of CoTx-101 offers potential for durable and long-lasting vision gains in treating wet AMD and DME.
Research
New 5-year Syfovre data indicates extended delay of GA progression
GALE extension study findings show delayed GA lesion growth by an estimated 1.5 years in patients receiving continuous treatment.
Pipeline
PolyActiva and RareSight to advance long-acting therapies for pediatric IRDs
Collaboration leverages PolyActiva’s PREZIA drug delivery platform to develop NCE-enabling pharmacologic drugs for early-onset vision loss.
Business
LambdaVision raises $7M to advance space-based artificial retina
Biotech is using space and microgravity to produce its protein-based artificial retina, designed to restore vision in retinal degenerative diseased patients.
Research
Antidepressant use may lower AMD risk
Study outlines potential explanations for link between antidepressant use and reduced risk of AMD onset and progression.
Research
RGC thickness may be early retinal indicator with oral HCQ
Screening with SD-OCT may aid in identifying patients with retinal toxicity before visual field loss.
Research
Advanced AMD linked to imbalanced gut microbiome
Though seemingly unrelated, gut flora may play a surprising role in the pathogenesis of age-related macular degeneration (AMD).
Research